Trial · NCT03338816
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Annualized Rate of Porphyria Attacks in Participants With Acute Intermittent Porphyria (AIP) | Placebo | 12.52 | 95% Confidence Interval 9.35 to 16.76 | annualized attack rate | |
| Annualized Rate of Porphyria Attacks in Participants With Acute Intermittent Porphyria (AIP) | Givosiran 2.5 mg/kg | 3.22 | 95% Confidence Interval 2.25 to 4.59 | annualized attack rate | |
| The Pharmacodynamic (PD) Effect of Givosiran on Urine Levels of Delta-aminolevulinic Acid (ALA) in Participants With AIP | Placebo | Month 3 | 19.965 | Standard Error 1.475 | mmol/mol creatinine (Cr) |
| The Pharmacodynamic (PD) Effect of Givosiran on Urine Levels of Delta-aminolevulinic Acid (ALA) in Participants With AIP | Givosiran 2.5 mg/kg | Month 3 | 1.756 | Standard Error 1.413 | mmol/mol creatinine (Cr) |
| The Pharmacodynamic (PD) Effect of Givosiran on Urine Levels of Delta-aminolevulinic Acid (ALA) in Participants With AIP | Placebo | Month 6 | 23.150 | Standard Error 2.534 | mmol/mol creatinine (Cr) |
| The Pharmacodynamic (PD) Effect of Givosiran on Urine Levels of Delta-aminolevulinic Acid (ALA) in Participants With AIP | Givosiran 2.5 mg/kg | Month 6 | 4.013 | Standard Error 2.352 | mmol/mol creatinine (Cr) |
| The PD Effect of Givosiran on Urine Levels of Porphobilinogen (PBG) in Participants With AIP | Placebo | 49.110 | Standard Error 4.959 | mmol/mol Cr | |
| The PD Effect of Givosiran on Urine Levels of Porphobilinogen (PBG) in Participants With AIP | Givosiran 2.5 mg/kg | 12.906 | Standard Error 4.642 | mmol/mol Cr | |
| Annualized Rate of Hemin Administration in Participants With AIP | Placebo | 29.71 | 95% Confidence Interval 18.41 to 47.94 | annualized rate of use | |
| Annualized Rate of Hemin Administration in Participants With AIP | Givosiran 2.5 mg/kg | 6.77 | 95% Confidence Interval 4.20 to 10.92 | annualized rate of use | |
| Annualized Rate of Porphyria Attacks in Participants With AHP | Placebo | 12.26 | 95% Confidence Interval 9.22 to 16.29 | annualized attack rate | |
| Annualized Rate of Porphyria Attacks in Participants With AHP | Givosiran 2.5 mg/kg | 3.35 | 95% Confidence Interval 2.37 to 4.74 | annualized attack rate | |
Area Under the Curve (AUC) of the Change From Baseline in Weekly Mean Score of Daily Worst Pain as Measured by the Brief Pain Inventory-Short Form (BPI-SF) Numeric Rating Scale (NRS) in Participants With AIP | Placebo | 5.286 | Inter-Quartile Range -23.048 to 11.145 | score on a scale*week | |
Area Under the Curve (AUC) of the Change From Baseline in Weekly Mean Score of Daily Worst Pain as Measured by the Brief Pain Inventory-Short Form (BPI-SF) Numeric Rating Scale (NRS) in Participants With AIP | Givosiran 2.5 mg/kg | -11.514 | Inter-Quartile Range -29.181 to 3.040 | score on a scale*week | |
| Average Change From Baseline in Weekly Mean Score of Daily Worst Pain as Measured by the Brief Pain Inventory-Short Form (BPI-SF) Numeric Rating Scale (NRS) in Participants With AIP | Placebo | 0.245 | Inter-Quartile Range -1.020 to 0.470 | score on a scale | |
| Average Change From Baseline in Weekly Mean Score of Daily Worst Pain as Measured by the Brief Pain Inventory-Short Form (BPI-SF) Numeric Rating Scale (NRS) in Participants With AIP | Givosiran 2.5 mg/kg | -0.506 | Inter-Quartile Range -1.309 to 0.143 | score on a scale | |
| AUC of the Change From Baseline in Weekly Mean Score of Daily Worst Fatigue Score as Measured by the Brief Fatigue Inventory-Short Form (BFI-SF) NRS in Participants With AIP | Placebo | -4.208 | Standard Error 4.689 | score on a scale*week | |
| AUC of the Change From Baseline in Weekly Mean Score of Daily Worst Fatigue Score as Measured by the Brief Fatigue Inventory-Short Form (BFI-SF) NRS in Participants With AIP | Givosiran 2.5 mg/kg | -11.148 | Standard Error 4.501 | score on a scale*week | |
| Average Change From Baseline in Weekly Mean Score of Daily Worst Fatigue Score as Measured by the Brief Fatigue Inventory-Short Form (BFI-SF) NRS in Participants With AIP | Placebo | -0.182 | Standard Error 0.209 | score on a scale | |
| Average Change From Baseline in Weekly Mean Score of Daily Worst Fatigue Score as Measured by the Brief Fatigue Inventory-Short Form (BFI-SF) NRS in Participants With AIP | Givosiran 2.5 mg/kg | -0.502 | Standard Error 0.200 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03338816/results